Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871097 | 0.92 | NPC1 (0.38) | NPC1DGAT1 | |
| SCHEMBL13866135 | 0.89 | NPC1 (0.39) | NPC1TOP2ASLC6A3MAPTTHRB | |
| SCHEMBL13865949 | 0.89 | NPC1 (0.35) | NPC1DGAT1MAPTALDH1A1 | |
| SCHEMBL14193452 | 0.88 | NPC1 (0.37) | NPC1DGAT1 | |
| SCHEMBL13866116 | 0.83 | NPC1 (0.41) | NPC1SLC6A3MAPTALDH1A1F11 | |
| SCHEMBL5667295 | 0.82 | CFTR (0.43) | NPC1MAPTALDH1A1POLB | |
| SCHEMBL13865869 | 0.81 | ALDH1A1 (0.38) | NPC1DGAT1SLC6A3MAPTALDH1A1 | |
| SCHEMBL13866073 | 0.81 | NPC1 (0.36) | NPC1DGAT1 | |
| SCHEMBL13866115 | 0.81 | CFTR (0.39) | NPC1MAPTALDH1A1 | |
| SCHEMBL13866138 | 0.80 | NPC1 (0.35) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | NPC1 1218/4885DGAT1 3570/4885TOP2A 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.